Online Database of Chemicals from Around the World

2-(环己烷羰基)-3,6,7,11b-四氢-1H-吡嗪并[6,1-a]异喹啉-4-酮
[CAS# 135526-78-2]

供应商
APIChem Technology Co., Ltd. 中国 询价快递  
+86 (571) 8678-2096
sales@apichemistry.com
化学品生产商(2009 年起)
Abacipharm Corporation 美国 询价快递  
+1 (410) 417-5545
sales@abacipharm.com
化学品生产商
Abblis Chemicals LLC 美国 询价快递  
+1 (832) 373-8299
info@abblis.com
化学品生产商
Achemica 瑞士 询价快递  
+41 (24) 466-2929
contact@achemica.com
化学品生产商(2010 年起)
Achemo Scientific Limited 香港 询价快递  
+852 3174-6428
sales@achemo.com
化学品生产商(2010 年起)
Asinex Ltd. 俄罗斯 询价快递  
+7 (495) 780-3415 / 780-3417
lsadovenko@asinex.com,
化学品生产商
ChemDiv, Inc. 美国 询价快递  
+1 (858) 794-4860
chemdiv@chemdiv.com
化学品生产商
ChemPacific Corp 美国 询价快递  
+1 (410) 633-5771
sales@chempacific.com
化学品生产商(1995 年起)
Glentham Life Sciences 英国 询价快递  
+44 (2033) 978-798
info@glenthamls.com
化学品供销商(2013 年起)
Interbioscreen Ltd. 俄罗斯 询价快递  
+7 (49) 6524-0091
screen@ibscreen.chg.ru
化学品生产商
基本信息
产品名称 2-(环己烷羰基)-3,6,7,11b-四氢-1H-吡嗪并[6,1-a]异喹啉-4-酮
英文名 2-(Cyclohexanecarbonyl)-3,6,7,11b-Tetrahydro-1H-Pyrazino[6,1-a]Isoquinolin-4-One
别名 2-(Cyclohexyl-Oxomethyl)-3,6,7,11B-Tetrahydro-1H-Pyrazino[6,1-A]Isoquinolin-4-One; 2-Cyclohexylcarbonyl-3,6,7,11B-Tetrahydro-1H-Pyrazino[6,1-A]Isoquinolin-4-One; Inchi=1/C19h24n2o2/C22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/H4-6,9,15,17H,1-3,7-8,10-13H
分子结构 CAS 登录号:135526-78-2, 2-(环己烷羰基)-3,6,7,11b-四氢-1H-吡嗪并[6,1-a]异喹啉-4-酮
分子式 C19H24N2O2
分子量 312.41
CAS 登录号 135526-78-2
分子行输入简码 SMILES C1=CC=CC4=C1C2N(C(CN(C2)C(C3CCCCC3)=O)=O)CC4
国际化学标识码 InChI 1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2
国际化学标识检索码 InChIKey FSVJFNAIGNNGKK-UHFFFAOYSA-N
物理化学性质
密度 1.2±0.1g/cm3 (计算值)
沸点 544.1±50.0°C at 760 mmHg (计算值)
闪点 254.6±22.5°C (计算值)
参考文献
(1) Kenneth E. Thummel and Danny D. Shen. Percentage Binding in Plasma, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Bound in Plasma' (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Bound in Plasma' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (22), Heparin (Extensive), Lithium (0), Mycophenolate (MPA: 97.5), Prednisolone (90-95 (<200 ng/ml), ~70(>1 microgm/ml)) and Rapacuronium (50-88) have not been provided here. In all, 280 drugs and their 'Bound in Plasma' values (%) are given in the files here.
(2) Kenneth E. Thummel and Danny D. Shen. Peak Time, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Time' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in hours unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Peak-Time' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (1.3), Enoxaparin (3), Epoetin Alfa (SC: 18, IP:12), Etanercept (SC-SD:72(48-96)), Filgrastim (4-5.8), Heparin (3), Interferon Alfa (IM:3.8,SC:7.3), Interferon Beta (SC:1-8), Lithium (IR:0.5-3, SR:2-6), Mycophenolate (MPA: 1.1-2.2), Prednisolone (1.5+-0.5), Sargramostim (A,SC: 1-3, C,SC:1.5-4) and Streptokinase (0.9+-0.21) have not been provided here. In all, 270 drugs and their 'Peak-Time' values are given in the files here.
(3) Kenneth E. Thummel and Danny D. Shen. Urinary Excretion, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023Urinary Excretion (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had Urinary Excretion values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (Low), Clavulanate (43+-14), Enoxaparin (43), Epoetin alfa (<3), Etanercept (Negligible), Heparin (Negligible), Lithium (95+-15), Mycophenolate (MPA: <1), Prednisolone (26+-9), Rapacuronium (6-22) and Streptokinase (0) have not been provided here. In all, 297 drugs and their Urinary Excretion values (%) are given in the files here.
(4) Kenneth E. Thummel and Danny D. Shen. Volume of Distribution, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Volume of Distribution' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in liters/kg units unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Volume of Distribution' values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (0.10+-0.01), Clavulanate (0.21+-0.05), Enoxaparin (0.12+-0.04), Epoetin Alfa (0.033+-0.013 (0.033-0.075)), Etanercept (0.11), Filgrastim (0.15), Heparin (0.058+-0.11) +- 0.1), Infliximab (0.043). Interferon Alfa (0.40+-0.19), Interferon Beta (2.9+-1.8), Lithium (0.66+-0.16), Mycophenolate (MPA: 3.6+-4), Prednisolone (0.42+-0.11), Rapacuronium (0.2-0.5), Sargramostim (A: -, C:2(0.4-18) liters/(m.m)) and Streptokinase (0.08+-0.04) have not been provided here. In all, 284 drugs and their 'Volume of Distribution' values are given in the files here.
(5) Kenneth E. Thummel and Danny D. Shen. Peak Concentration, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Concentrations' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. The units are indicated along with the values. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Structures (and values) for Alteplase (t-PA) (973+-133 ng/ml), Clavulanate (2.8 micro g/ml), Enoxaparin (ACLM: 145+-45 ng/ml, BCLM: 414+-87 ng/ml), Epoetin Alfa (SC: 176+-75 U/l, IP: 375+-123 U/l), Etanercept (IV:2.32 micro-g/ml, SC-SD:1.2 micro-g/ml, SC-MD 3 micro-g/ml), Filgrastim (SC: 4 and 49 ng/ml), Heparin (70+-39 ng/ml), Infliximab (118 micro-g/ml), Interferon Alfa (IV: ~13 ng/ml, IM: 2.0 (1.5-2.6) ng/ml, SC: 1.7 (1.2-2.3) ng/ml), Interferon Beta (IV: 1491+-659 IU/ml, SC: 40+-20 IU/ml), Lithium (IR: 1-2 mM, SR: 0.7-1.2 mM), Mycophenolate (MPA: 8-19 micro-g/ml), Prednisolone (458+-150 ng/ml), Rapacuronium (6-20 micro-g/ml), Sargramostim (A, IV: 5ng/ml, A, SC: 1.5 ng/ml, C, IV: 100 ng/ml, C, SC: 10 ng/ml) and Streptokinase (188+-58 IU/ml) have not been provided here. In all, 304 drugs and their 'Peak-Concentration' values are given in the files here.
市场分析报告
请浏览2-(环己烷羰基)-3,6,7,11b-四氢-1H-吡嗪并[6,1-a]异喹啉-4-酮市场分析报告总目录
相关产品
磷酰腺苷二磷酰核糖  二羟基丙酮硫酸盐  (2S,3R)-3-氯-2-[(2E)-3,7-二...  4',5'-二去氢-4'-脱氧-2',19'-二氧...  乙基4-(甲氧基甲基)-6-丙氧基-9H-吡啶并[...  反式-环庚烷-1,2-二醇  甲磺酰基亚胺基二甲基硫(IV)  5-丁基-5-苯基巴比妥酸  甜周围假雄蕊素A  甜周围假雄蕊素B  甜周围假雄蕊素C  (2,5-二甲氧基苯基)甲基肼  [(2S,3S,4R,5S)-4-乙酰氧基-5-[...  L-天冬氨酰胺酰甘氨酰-L-alpha-天冬氨酰-...  精氨酰-甘氨酰-天冬氨酰-水蛭素(53-64)